This study supported an anti-proliferative role for SIK1 in hypoxia-induced PAH remodeling and suggested that SIK1 might be a potential target for the treatment of PAH (Pu et al., 2022). This evidence concerns the gene SIK1 and pulmonary arterial hypertension.